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 The presence of both fungal antibodies and antigens in the serum of a patient with 
acute zonal occult outer retinopathy caused by Candida famata infection has been 
examined. Antibodies against C. famata increased until 1999-2000 when antifungal 
treatment was initiated. The antibodies were detected by ELISA and immunofluorescence 
analysis using C. famata. These antibodies were not immunoreactive against several 
candida species tested. Positive immunofluorescence was obtained with IgM, but not IgA, 
IgG or IgE. Moreover, the IgM response disappeared several months after treatment with 
antifungal compounds, despite the fact that C. famata antigens were present in blood. 
Finally, a sensitive test was developed to assay for the presence of C. famata antigens in 
serum. This method is based on the immunodetection of fungal antigens transferred to a 
nitrocellulose membrane that is incubated with rabbit antibodies rose against C. famata. 
According to this method, the infection remitted with antifungal treatment.  
 
 2
INTRODUCTION 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
 The immunologic response to fungal infections in humans is complex and still 
subject to much debate (Coleman et al., 1998; d'Ostiani et al., 2000; Gil, 1997; Lopez-
Ribot et al., 2004; Mencacci, 1999; Pfaller, 1996; Shoham & Levitz, 2005). Cellular 
response, particularly macrophage function may be crucial to combat systemic infections 
produced by different fungi (Badauy et al., 2005; d'Ostiani et al., 2000; Simitsopoulou & 
Roilides, 2005; Villar et al., 2005). However, the importance of a robust antibody response 
to candida infections has also been documented (Fernandez-Arenas et al., 2004; Mencacci, 
1999; Witkin et al., 1983). The fact that systemic candidiasis is much more common in 
immunocompromised patients evidences the key role of the immune system in preventing 
this infection (Altamura et al., 2001; Clemons et al., 2000; Ruhnke, 2006; Sims et al., 
2005).  Cellular immune response, together with the humoral response and innate immunity 
are most likely necessary for an efficient control of this type of systemic infection 
(Altamura et al., 2001; Lopez-Ribot et al., 2004). Although many studies have described 
the immune response in human candidiasis (Lopez-Ribot et al., 2004; Mencacci, 1999; 
Rozell et al., 2006), hardly any have attempted to characterize the antibodies of patients 
infected with C. famata.  
 Candida spp. accounts for a large percentage of human fungal infections. Apart 
from Candida albicans, which represents about 50% of blood isolates (Canteros et al., 
1994; Peres-Bota et al., 2004), other species such as C. glabrata, C. parapsilosis, C. 
tropicalis, and C. krusei, have been found in the blood of infected patients (Al-Hedaithy, 
2003; Almirante et al., 2006; Brandt et al., 2000; Fanci et al., 2005; Veldman et al., 2006; 
Wagner et al., 2005; Yang et al., 2003). Viable C. famata has been found in about 1-2% of 
patients suffering systemic candidiasis (Al-Hedaithy, 2003; Canteros et al., 1994; Krcmery 
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& Barnes, 2002; Peres-Bota et al., 2004; Pfaller et al., 2003; Prinsloo et al., 2003; Ruhnke, 
2006; Tortorano et al., 2006; Yamamoto et al., 2002), but analysis of the presence of 
genomes by PCR yields a different percentage (Deventer, 1995; Khan & Mustafa, 2001; 
Pryce et al., 2003). Although C. famata is considered non-pathogenic (Andrighetto et al., 
2000; Gardini et al., 2001), it has been found in tissues as diverse as bone, blood or the 
CNS, and is associated with vision problems (Krcmery & Kunova, 2000; Prinsloo et al., 
2003; Rao et al., 1991; St-Germain & Laverdiere, 1986). Recent evidence suggests that C. 
famata was the etiological agent responsible for acute zonal occult outer retinopathy 
(AZOOR). We now report in detail the antibody response in an AZOOR patient previously 
described (Carrasco et al., 2005). We also monitored the course of infection using different 
methods. Correct diagnosis of disseminated candidiasis is still elusive in some patients; 
thus, different approaches are needed to demonstrate disseminated fungal infection 
(Ellepola & Morrison, 2005; Pontón, 2006; Yeo & Wong, 2002). In most hospitals, 
hemocultures are the main routine assay for detecting disseminated candidiasis (Ellepola & 
Morrison, 2005). However, unlike systemic candidiasis, viable candida cells are very 
seldom present in disseminated infections. PCR can overcome this problem but at least one 
fungal genome per assay must be present to determine the presence of yeast cells in blood 
(Bretagne & Costa, 2005). Other methods are based on detecting fungal metabolites or 
other components, like proteins or polysaccharides in blood serum (Ishibashi et al., 2005; 
Mitsutake et al., 1996; Pontón, 2006). Some of these methods detect specific proteins, such 
as glycolytic enzymes, heat-shock proteins or secreted proteases. The use of immunological 
assays to evidence the presence of these proteins in human blood serum constitutes a more 
sensitive test to diagnose disseminated candidiasis. Diverse commercial kits have been 
developed to assay the presence of polysaccharides such as manans or glucans in serum. 
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We compared all these techniques in serum samples taken at different times from a patient 
infected with C. famata. Our results suggest that analysis of fungal proteins in serum 
constitutes the most sensitive test to monitor the course of this infection.  
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Yeast growth. The yeast was grown in YEPD medium (1% yeast extract, 2% peptone, 2% 
glucose) by incubation at 30°C. The same medium, containing agar, was used to isolate 
individual yeast colonies.  
Antibodies. Rabbit antisera against different yeast species were obtained by inoculation of 
0.5 ml of phosphate buffered sorbitol (PBS) containing 1 or 2 mg of yeast after autoclaving 
and lyophilization. Each inoculum had been previously mixed with the same volume of 
Freund’s adjuvant. Rabbits were inoculated up to four times, and the antibody titer and 
specificity of the sera were tested by immunofluorescence and Western blotting. 
Immunofluorescence and immune-electron microscopy. For C. famata, 1 ml of culture 
was placed in 1.5 ml microcentrifuge tubes. Cells were washed with PBS, incubated with 
50 mM ammonium chloride for 10 min, and washed three times with PBS-Tween 20. Cells 
were then treated with the different sera diluted 1:500 in PBS-Tween 20, at 37ºC for 2 h, 
washed again with PBS-Tween 20 and incubated with the secondary antibody. Goat anti-
human immunoglobulins IgA, IgM and IgG (Sigma), or rabbit anti IgG+IgA+IgM 
(Abcam), conjugated to fluorescein antibodies, were added at 1:500 dilution; in some cases 
anti-IgG4 and IgE antibodies were used (a generous gift from M. Lombardero, ALK, 
Abelló, Madrid). In these cases, samples were then incubated with an anti-Ig fluorescein-
conjugated antibody. The samples were incubated at 37ºC for another hour. The cells were 
then washed, resuspended in PBS and mounted on slides with a drop of Depex (Serva). 
Finally, the cells were observed under a fluorescence microscope. For the remaining 
candida species, the commercial kit Euroimmun (Medizinische Labordiagnostika AG) was 
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used in accordance with the manufacturer’s instructions and using the same serum dilutions 
as for C. famata. For immune electron microscopy, we
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 followed the protocol described 
elsewhere (Wright et al., 1988), with a few modifications: the cells were fixed for 2 h at 
room temperature in 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) and washed 
after postfixation with 0.15% tannic acid in 0.05 M cacodylate buffer (pH 7.2). Cells were 
finally embedded in Epon (TAAB laboratories, Berkshire, United Kingdom). The sections 
were rehydrated in PBS and immersed in 0.5 M NH2Cl for 15 minutes. Samples were then 
blocked with 1% BSA in PBS, incubated for 1 hour with the primary antibody diluted in 
1% low-fat dry milk in PBS at room temperature, and subsequently washed with 0.1% BSA 
in PBS. After washing, secondary antibody conjugated to colloidal gold particles was added 
at 1:10000 dilution in PBS.  Finally, samples were washed again with PBS and once again 
with triply-distilled water. The samples were analyzed with a JEOL 1010 electron 
microscope.  
ELISA. Enzyme-linked immunosorbent assay (ELISA) was carried out as previously 
described (Carrasco et al., 2005). Briefly, a C. famata cell suspension diluted in PBS was 
seeded in ELISA microtiter plates (Maxisorp; Nunc). Blockade was carried out in PBS 
containing 3% low-fat dry milk and 0.2% Tween 20. Sera from the AZOOR patient were 
added at 1:200 dilution and plates were subsequently incubated with goat anti-human 
(heavy and light chain) immunoglobulin G horseradish peroxidase-conjugated antibodies 
(Pierce) and washed five times. Color development was accomplished by incubation with o-
phenylenediamine (Sigma) and measured at 490 nm in a microplate reader (EL340; BIO-
TEK Instruments). 
 7
Western blot assays. Yeast proteins were precipitated with trichloroacetic acid (10%) and 
fractionated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
with 15% polyacrylamide, transferred to nitrocellulose membranes by wet immunotransfer, 
and processed for Western blotting. Blocking, incubation with antibodies and washing were 
performed as described for ELISA. Goat anti-human IgM horseradish peroxidase-
conjugated antibodies (Amersham Biosciences) and the ECL kit (Amersham) were used to 
detect bound antibodies. Chemiluminescence was detected by exposure to Agfa X-ray film. 
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PCR analyses. The DNA was extracted from serum or whole blood. To this end, 200 μl of 
serum were boiled for 10 minutes and then incubated for 2 h at 37ºC with Zimolase (ICN) 
and for a further 2 hours at 58ºC with proteinase K (Sigma). Then 200 μl of a detergent 
buffer were added and samples were boiled again for 10 minutes before adding 1 ml of 
phenol:chloroform (1:1) (Amersham) and centrifuging at 20000 × g for 20 min. The upper 
aqueous phase was recovered and washed twice with ethyl ether. The DNA was 
precipitated by addition of 3 volumes of absolute ethanol (Merck) (−20°C) to the aqueous 
phase. After storing the samples overnight at −20°C, the DNA was then centrifuged at 
20000 × g for 20 min. Pellets were dried and resuspended in H2O. The DNA preparations 
were incubated with oligonucleotides that hybridize to the rRNA genes (Li et al., 2003; 
Nishikawa et al., 1999). In this manner, the first ITS region was amplified. The amplified 
product was analyzed by agarose gel electrophoresis. The corresponding band was 
sequenced to determine unequivocally the presence of C. famata genomes. Real time 
quantitative PCR was carried out in an ABI PRISM 7000 thermocycler (Applied 
biosystems). The reaction mix was prepared with 0.9 µM of each oligonucleotide and 0.25 
µM of TaqMan probe in a final volume of 20 µl, to which 50 ng of DNA were added. The 
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concentration of DNA template was normalized by previous PCR reactions with specific 
oligonucleotides, in which DNA was denatured at 95ºC for 10 minutes and amplified in 40 
cycles of 15 seconds at 95ºC and 1 minute at 60ºC. Analysis of the data was done using the 
SDS 7000 (1.1) software.  
Dot-Blot analyses. 200 μl of different serum dilutions in TBS were added to each well. 
Samples were blotted onto a 45 mm nitrocellulose membrane (Bio-Rad) previously 
hydrated in TBS for 10 minutes using the Bio-Dot SF apparatus (Bio-Rad). After blotting, 
the membrane was processed and developed as described above for Western blotting. The 
primary antibodies, rabbit polyclonal antibodies rose against C. famata, C. albicans, C. 
glabrata, C. parasilopsis, Rhodotorula mucilaginosa or Saccharomyces cerevisiae were 
used at 1:1000 dilution. We used a donkey anti-rabbit IgG horseradish peroxidase-
conjugated antibody (Amersham Biosciences) at 1:5000 dilution as secondary antibody. 
Detection of fungal polysaccharides. The presence of manoses and beta-1,3 glucan in 
serum was detected using the Platelia Candida AG test (Bio-Rad), as described by the 
manufacturer, or the Fungitell Serum Assay kit, performed by Fontlab laboratories 
(Barcelona, Spain) (Pazos et al., 2005). 
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 The characteristics of our patient have been been previously described (Carrasco et 
al., 2005). Briefly, the patient was diagnosed with acute zonal occult outer retinopathy 
(AZOOR) in 1996 (aged 47). In 1999, C. famata was isolated from conjunctival exudate 
and blood. At the end of this year, intermittent antifungal treatment was administered as 
described (Carrasco et al., 2005). Initially, the presence of anti-C. famata antibodies from 
serum obtained from different years was analyzed by ELISA (Figure 1A). The C. famata 
antibody titer increased until 1999. After administration of antifungal compounds, a clear 
decrease in the antibody titer was observed and it has remained low ever since. Analysis of 
these antibodies by immunofluorescence using C. famata also corroborated this observation 
(Figure 1B). Thus, positive immunofluorescence appeared with the sera obtained in June 
1999, September 1999 and January 2000. Low reactivity was found with sera from June 
1996 and August 2001, while no antibodies were detected from serum obtained in October 
2005. The immunofluorescence observed with other yeast species was similar to the 
negative control without primary antibody. Only a slight reaction with C. tropicalis 
apperaed suggesting that the antibodies were fairly specific against C. famata in the 
immunofluorescence test. In our experience, some human sera do react with C. tropicalis in 
the Euroimmune test. Therefore, we consider this reactivity as non-specific. Next, we 
wanted to analyze the type of antibodies present in the positive serum from 1999. For this, a 
second anti-human antibody specific for IgA, IgM, IgG, IgG4 or IgE was employed after 
incubation of C. famata with this serum (Figure 2). Interestingly, this assay revealed the 
presence of IgM but not IgG antibodies, even though the patient had been infected over 
several years. On the other hand, these IgM antibodies were not cross-reactive with C. 
albicans (Figure 2). This serum was also analyzed by Western blotting against C. famata 
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proteins. Figure 3A shows that there are two yeast proteins that immunoreact better with 
serum from September 1999. These two proteins, of about 41 and 30 KDa, reacted more 
weakly with sera from October 2005, January 2006 and the control healthy donor. In 
addition, there are other proteins that immunoreact non-specifically with all the sera 
employed, such as the 47 KDa protein. Western blotting using C. albicans proteins reveals 
a low reactivity with the patient’s serum, as compared to a serum from a control patient 
infected with C. albicans. Moreover, no immunoreactivity was found against proteins from 
Cryptococcus magnus (Figure 3A). Immuno-gold using electron microscopy analysis was 
carried out (Figure 3B). This human antiserum clearly reacted with antigens at or in close 
proximity to the plasma membrane of C. famata. For comparison, a rabbit antiserum rose 
against this yeast was employed. It was noteworthy that both human and rabbit antisera 
recognized a similar structure close to the plasma membrane. 
 Since the vision symptoms have not yet fully resolved, we tried to detect the 
presence of C. famata infection using PCR. DNA was extracted from serum submitted to 
PCR out using oligonucleotides that amplify the first intervening sequence between the 
rRNA genes, as described. Real-time quantitative PCR using TaqMan probes was carried 
out with different samples (Figure 4A). Evidence for the presence of C. famata genomes in 
the blood sera of this patient was found in the samples from October 1996 and June 1997, 
despite the fact that no viable yeast cells were recovered from these hemocultures. Further, 
the presence of fungal genomes clearly diminished from June 1999 even though some 
symptoms of infection remained in this patient, such as the appearance of C. famata 
genomes in conjunctival exudates. The decrease of fungal genomes in blood since October 
1996 probably corresponded to the discontinuation of immunosuppression therapy from the 
end of that year. These findings indicate that the presence of C. famata can be evidenced by 
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PCR in samples that contain few antibodies and, conversely, no fungal genomes are found 
at the peak of the antibody response. To confirm that the fungal genomes amplified in 
figure 4A were from C. famata, the amplified product obtained from another PCR reaction 
was separated by agarose gel electrophoresis (Figure 4B). A single product of about 240 nt 
is apparent in the serum from June 1997, which corresponds to the same band obtained 
from C. famata DNA. This band was extracted and sequenced revealing that it indeed 
belonged to C. famata. Although no fungal genomes were detected by PCR from January 
2000, abundant C. famata genomes were evidenced in a number of conjunctival exudates 
obtained up until May 2006 (data now shown).  
 Since no C. famata genomes were detected in sera from recent years, we aimed to 
develop a system to detect the presence of fungal antigens in the blood serum. Our attempts 
to find fungal proteins by Western blotting using a rabbit antiserum rose against C. famata 
were unsuccessful. A much more sensitive test is the detection of proteins using the dot-blot 
assay. In this test, different serum dilutions are transferred to a nitrocellulose membrane 
that is incubated with the rabbit anti-C. famata antibodies. Using this assay, the presence of 
C. famata antigens is evident (Figure 5A) and decreased over the years (Figure 5B). This 
test has the advantage that it can be quantitated by densitometry. Thus, with the 1/500 
dilution, there is no immunoreactivity with sera from healthy donors (Figure 5A). On the 
other hand, the patient serum did not react with rabbit pre-immune serum. Notably, some 
serum samples from the patient gave high test values, particularly before antifungal 
treatment was initiated. Despite prolonged administration of antifungal compounds, there 
was still evidence of fungal antigens using the dot-blot assay. Voriconazole treatment was 
initiated at the beginning of March 2006 but, curiously, there was an increase in the yeast 
antigens found in the blood, perhaps reflecting the action of this antifungal compound in 
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tissues where infection persisted. For comparison, the same serum samples were tested for 
the presence of fungal polysaccharides (Ishibashi et al., 2005). The Bio-Rad test Platelia 
Candida AG gave negative results in our samples (data not shown), whereas positive values 
were found when the Fungitell kit was employed. This last test, which measures β-1,3 
glucans, indicated the presence of this polysaccharide in the patient’s blood over several 
years, but with large variations in the different samples assayed. The patient had become 
negative for this test from January 2006 but tested positive with the dot-blot assay. By 
comparison, the dot-blot assay is much more sensitive than the Fungitell test (Matthews, 
1998; Mitsutake et al., 1996; Reboli, 1993), although both assays could be run to confirm 
the existence of fungal infection. Both assays could be useful for a first diagnosis, but the 
follow-up of the patient should be carried out with the dot-blot test. Serum from a patient 
may even test negative for both assays even though some residual infection remains in 
some tissues of the body.  
 Finally, the specificity of the dot-blot assay was analyzed employing several rabbit 
polyclonal antibodies rose against different yeast species (C. albicans, C. parapsilosis, C. 
glabrata, Rhodotorula mucilaginosa, and Saccharomyces cerevisiae). The potency and 
specificity of these antibodies were estimated using immunofluorescence and Western blot 
assays against the corresponding yeasts. Specific reactivity of the serum was exhibited 
against C. famata antibodies, whereas partial cross-reactivity was found with rabbit 
antibodies rose against other yeasts but not with the anti-S. cerevisiae antibodies (Figure 6). 
In conclusion, these findings indicate that patient serum contains antigens that are 
preferentially recognized by C. famata antibodies and that partially cross-react with 
antibodies against other related yeast species.  
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In this work, we have examined in detail one patient infected with C. famata, in 
order to generalize the findings reported, more patients should be studied. Little is known 
about the human immune response to disseminated infection by C. famata. In principle, this 
yeast has been classified as non-pathogenic and so does not produce an overt inflammatory 
reaction. C. famata may use different strategies to evade immune response, one of them 
being the production of superoxide dismutase that interferes with macrophage function 
(Garcia-Gonzalez & Ochoa, 1999). Other strategies common to other yeasts may be the 
production of a mucous environment, as well as precipitation of calcium carbonate at the 
sites of infection as a result of the drop in pH associated with fungal metabolic activity. In 
the patient studied here, the immune response as regards to antibody production was rather 
weak. The IgM response quickly disappeared after several months of antifungal treatment, 
even though the infection still remains in the periocular mucosa and probably in the retina 
and optic nerve. The cellular immune response of this patient measured by the presence of 
specific T-lymphocytes was also low, despite the fact that he was not immunocompromised 
and was healthy apart from the vision problems. The rather low stimulation of the immune 
system observed in this patient may thus be one of the reasons for the prolonged infection 
described. The stimulation of the immune system certainly may help to combat and 
eventually to eradicate this infection (Lopez-Ribot et al., 2004).  
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 From the point of view of diagnosis, we have developed and compared different 
approaches to detect C. famata infection. Although the presence of the antibody response 
should be assayed, like other candida infections, this test is of limited diagnostic value 
(Quindos et al., 2004). It must be stressed that the presence of viable candida in blood was 
very rarely detected in our patient. Once again, although hemoculture should be done, the 
absence of yeast growth does not rule out the possibility of a systemic or disseminated 
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infection (Einsele et al., 1997). The use of PCR is of greater value. Although this technique 
is very sensitive and we can detect a single genome copy present in the test tube in our 
assays, fungal genomes may not be circulating in the blood, i.e. the yeast may be located at 
focuses in different tissues without any cells, whether dead or alive, entering the 
bloodstream (Khan & Mustafa, 2001). Under these conditions, it is possible that the 
synthesis of polysaccharides may occur or export proteins could reach the blood and these 
could be detected in the serum (Mitsutake et al., 1996; Pontón, 2006). In this regard, it is of 
special interest the system developed to analyze C. famata antigens by dot blot using a 
rabbit antiserum. This assay is very sensitive, since the presence of these antigens can be 
detected at 1/500 or even 1/1000 dilutions. With this test, we can monitor the efficacy of 
the different antifungal treatments. The amount of protein detected by this method is in the 
femtomolar range, which is below the limit of detection of Western blotting.  
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Figure 1: (A) ELISA to determine the presence of antibodies against C. famata in patient 
sera from different years. The assay was carried out as described in Materials and Methods. 
(B) Immunofluorescence analysis of different yeasts using different patient sera. In the case 
of C. famata, the protocol described in Materials and Methods was followed. As positive 
control, rabbit antiserum against C. famata was employed; for the negative control, PBS 
instead of primary antibody was added. The commercial kit for immunofluorescence, 
Euroimmun, was used for the remaining yeast species analyzed. The controls were those 
provided by the commercial kit. 
 
Figure 2: Antibody type examined by immunofluorescence with the serum from 1999. C. 
famata cells were treated as described in Materials and Methods and incubated with patient 
serum from June 1999. Then, a range of anti-human antibodies specific for different 
immunoglobulins were employed as secondary antibody. As a negative control, PBS, 
instead of  primary antibody was added. 
 
Figure 3: (A) Western blot of C. famata proteins. Different human sera were assayed as 
indicated in the Figure. The secondary antibody recognized IgM immunoglobulins. Serum 
dilutions were at 1/4000, whereas the secondary antibody was employed at 1/10000. (B) 
Immuno electron microscopy of C. famata cells. Yeast cells were incubated with patient 
serum or, as a control, with the rabbit serum obtained against C. famata, then incubated 
with the secondary antibody conjugated with colloidal gold. 
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Figure 4: Detection of C. famata genomes by PCR. (A) Determination of the number of C. 
famata genomes in 200 μl of serum by quantitative PCR, carried out as described in 
Materials and Methods. (B) PCR analysis of different serum samples obtained from the 
patient on the dates indicated above each lane. PCR assays were carried out with 
oligonucleotides that amplify a region of the rRNA internal transcribed spacer genes. 
Control 1: positive control of DNA extracted from C. famata; Control 2: negative PCR 
control without DNA; Control 3: negative control of DNA extraction of phosphate buffer. 
To the left of the gel the DNA markers in base units are indicated. 
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Figure 5: (A) Dot-blot detection of C. famata antigens in patient sera. Different dilutions of 
sera were blotted to a nitrocellulose membrane, which was incubated with the rabbit 
antiserum rose against C. famata. Rabbit pre-immune serum and sera from two healthy 
donors (control 1 and 2) were used as controls. (B) Densitometric values of the 1/500 
dilution from the dot blot of C. famata antigen in different serum samples obtained from the 
patient between 1996 and 2006. (C) Detection of fungal polysaccharides in different serum 
samples using the Fungitell commercial kit. The discontinuous line indicates the minimum 
level of antigen necessary for the sample to be considered as positive. Control 1 and 2 are 
sera from healthy donors. 
 
Figure 6: Dot-blot analysis of the patient serum using rabbit antibodies rose against 
different yeasts. Dilutions from 1:200 to 1:5000 of the serum obtained from the patient in 
June 1996 were blotted and the nitrocellulose membrane was incubated with different 
antisera rose against the indicated species. The rabbit antisera were obtained as described in 
Materials and Methods. 
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